IMDX
Insight Molecular Diagnostics Inc.
3.40$
-0.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 41.3% | 42.2% | 74.4% | 51.9% | 56.5% | 60.0% | 38.0% | 32.4% | 46.5% | 56.5% | 1,992.2% | 34.3% | 88.8% | |
| 58.7% | 57.8% | 25.6% | 48.1% | 43.5% | 40.0% | 62.0% | 67.6% | 53.5% | 43.5% | -1,892.2% | 65.7% | 11.2% | |
| 525.9% | 509.3% | 1,313.6% | 2,358.7% | 2,449.6% | 151.9% | 136.8% | 633.4% | 1,491.5% | 511.8% | 14,375.0% | 1,877.0% | 1,125.3% | |
| 815.1% | 724.0% | 1,918.2% | 2,314.4% | 2,230.4% | 212.7% | 145.7% | 511.0% | 978.8% | 350.9% | 9,346.9% | 1,202.1% | 742.9% | |
| 1,850.1% | 1,576.0% | 5,290.9% | 4,501.9% | 11,795.7% | 2,303.0% | 380.0% | 1,967.6% | 4,302.7% | 917.1% | 30,392.2% | 4,836.4% | 2,569.9% | |
| -1,791.4% | -1,518.2% | -5,265.3% | -4,453.8% | -11,752.2% | -2,262.9% | -318.0% | -1,900.0% | -4,249.2% | -873.6% | -32,284.4% | -4,770.7% | -2,558.7% | |
| 3.0% | 3.3% | 8.5% | 7.7% | 27.0% | 2.0% | 1.4% | 4.8% | 11.2% | 2.3% | 71.9% | 8.4% | 5.9% | |
| -1,799.8% | -1,512.6% | -5,186.9% | -4,355.8% | -11,733.0% | -2,255.1% | -312.0% | -1,880.7% | -4,174.6% | -2,015.4% | -13,406.3% | -4,711.3% | -2,955.6% | |
| 1,060.7% | 214.9% | 4,971.6% | – | – | – | – | – | – | – | – | – | – | |
| -1,799.8% | -1,512.6% | -5,186.9% | -4,355.8% | -11,733.0% | -2,255.1% | -312.0% | -1,880.7% | -4,174.6% | -2,015.4% | -13,406.3% | -4,711.3% | -2,955.6% | |
| -1,698.1% | -1,410.0% | -4,988.1% | -4,034.6% | -11,410.4% | -2,215.2% | -287.7% | -1,768.0% | -3,938.8% | -1,963.7% | -11,362.5% | -4,424.7% | -2,803.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.